Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women

Journal of Glaucoma

Volumn 8, Issue 6, 1999, Pages 388-395

  Bartlett, Jimmy D ^e   Olivier, Mildred ^a   Richardson, Thomas ^b   Whitaker Jr , Roy ^c   Pensyl, Denise ^b   Wilson, M Roy ^d  

^a Midwest Glaucoma Center   (United States)

^b Charles Circle Eye Consultants ^*

^c Georgia Eye Institute   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Carteolol hydrochloride; Central nervous system; Ocular hypertension; Plasma lipids; Postmenopausal black women; Primary open angle glaucoma; Timolol maleate

Indexed keywords

CARTEOLOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEGRO; OPEN ANGLE GLAUCOMA; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0033278367     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-199912000-00009     Document Type: Article

References (41)

1. Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol 1979;97:656-658.
2. Diamond GR, Werblin TP, Richter R, Radius RL. Extended clinical studies using timolol in patients with ocular hypertension and chronic open-angle glaucoma. Glaucoma 1979;1:63-68.
3. Merte HJ, Merkle W. Experiences in a double-blind study with different concentrations of timolol and pilocarpine. Klin Monatsbl Augenheilkd 1980;177:443-450.
4. Widder W. Timolol eye drops in ophthalmological practice. Klin Monatsbl Augenheilk 1980;176:430-440.
5. Zimmerman T, Baumann D, Hetherington J. Side effects of timolol. Surv Ophthalmol 1983;28:243-249.
6. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736-738.
7. Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 1981;245:1460-1461.
8. Laursen SO, Bjerrum P. Timolol eye drop-induced severe bronchospasm. Acta Med Scand 1982;211:505-507.
9. Leier CV, Baker D, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104:197-199.
10. Stewart WC. Carteolol, an ophthalmic beta-adrenergic blocker with intrinsic sympathomimetic activity. J Glaucoma 1994;3:339-345.
11. Schnaudigel O-E, Becker H, Fuchs H-B. Carteolol: praxisgerechte prufung von wirksamkeit und vertaglichkeit eines neuen betablockers in der behandlung des glaukoms. Klin Monatsbl Augenheilkd 1988;192:248-251.
12. Scoville B, Krieglstein GK, Lthen E, Yokoyama S, Yokoyama T. Measuring drug-induced eye irritation: a simple new clinical assay. J Clin Pharmacol 1985;25:210-218.
13. Stewart WC, Dubiner HB, Mundorf TK, Laibovitz RA, Sall KN, Katz LJ. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol 1999;127:142-147.
14. Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988;105:150-154.
15. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. JAMA 1991;266:369-374.
16. Mason RP, Kosoko O, Wilson MR, Martone JF, Cowan CL, Gear JC. National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. I. Prevalence findings. Ophthalmology 1989;96:1363-1368.
17. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Jaritt JC. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 1991;325:1412-1417.
18. Hiller R, Kahn H. Blindness from glaucoma. Am J Ophthalmol 1975;80:62-69.
19. Derogatis LR. SCL-90-R (Symptom Checklist-90-R): Administration, Scoring, and Procedures Manual. Third edition. Minneapolis: National Computer Systems, 1994.
20. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-552.
21. Burstein NL. Ophthalmic drug formulations. In, Bartlett JD, Jaanus SD (eds.): Clinical Ocular Pharmacology. Third edition. Boston: Butterworth-Heinemann, 1995;21-45.
22. Mansour AM. Tolerance to topical preparations: cold or warm? Ann Ophthalmol 1991;23:21-22.
23. Kuppens EVMJ, van Best JA, Sterk CC, de Keizer RJW. Decreased basal tear turnover in patients with untreated primary open-angle glaucoma. Am J Ophthalmol 1995;120:41-46.
24. Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol 1997;123:465-477.
25. Westfall DP. Adrenoceptor antagonists. In, Craig CR, Stitzel RE (eds.): Modern Pharmacology with Clinical Applications. Fifth edition. Boston: Little, Brown, 1997;123-134.
26. Bartlett JD, Novack GD, Hiett JA, Jaanus SD, Sharir M. Antiglaucoma drugs. In, Bartlett JD, Jaanus SD (eds.): Clinical Ocular Pharmacology. Third edition. Boston: Butterworth-Heinemann, 1995;183-248.
27. Weiner N, Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous systems. In, Gilman AG, Goodman LS, Rall TW, Murad F (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: MacMillan, 1985;66-99.
28. Coleman AL, Diehl D, Jampel HD, Bachorik PS, Quigley HA. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990;108:1260-1263.
29. Vogel R. Topical timolol and serum lipoproteins. Arch Ophthalmol 1991;109:1341-1342.
30. Freedman SF, Freedman NJ, Shields MB, Lobaugh B. Samsa GP, Keates EU. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993;116: 600-611.
31. Gillium RF, Mussolino ME, Madans JH. Coronary heart disease risk factors and attributable risks in African-American women and men: NHANES I epidemiologic follow-up study. Am J Public Health 1998;88:913-917.
32. Potts JL, Thomas J. Traditional coronary risk factors in African-Americans. Am J Med Sci 1999;317:189-192.
33. Wild SH, Laws A, Fortmann SP, Varady AN, Byrne CD. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. Ann Epidemiol 1995;5:432-439.
34. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men: the NHANES I epidemiologic follow-up study. Ann Intern Med 1997; 127:111-118.
35. Karter AJ, Gazzaniga JM, Cohen RD, Casper ML, Davis BD, Kaplan GA. Ischemic heart disease and stroke mortality in African-American, Hispanic, and non-hispanic white men and women. 1985 to 1991. West J Med 1998;169:139-145.
36. Gillum RF, Mussolino ME, Sempos CT. Baseline serum total cholesterol and coronary heart disease incidence in African-American women: the national health and nutrition examination survey (NHANES I) epidemiologic follow-up study. Am J Cardiol 1998; 81:1246-1249.
37. Gillum RF. Epidemiology of hypertension in African-American women. Am Heart J 1996;131:385-395.
38. Novack GD, Leopold IH. The toxicity of topical ophthalmic beta-blockers. J Toxicol Ocular Toxicol 1987;6:283-297.
39. Derogatis LR, DellaPietra L. Psychological tests in screening for psychiatric disorders. In, Maruish M (ed.): The Use of Psychological Testing for Treatment Planning and Outcome Assessment. Hillsdale, NJ: Lawrence Erlbaum, 1994:144-172.
40. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-1095.
41. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS). III. Baseline characteristics of black and white patients. Ophthalmology 1998;105:1137-1145.